Matt Sullivan is a member of our Healthcare & Life Sciences practice, and has nearly 20 years of industry and consulting experience.
In the healthcare sector, Matt has advised large biopharmaceutical clients, biotechnology firms, life science tools firms, diagnostic companies, and private investment funds. He holds deep expertise in asset screening, due diligence, and corporate and brand strategy.
In the biopharmaceutical space, Matt has worked across a wide range of therapeutic areas, including oncology, cardiovascular, immunology and rare diseases, with a specific focus on advanced modalities including cell and gene therapy. He has worked with biopharma clients on topics including asset valuation and due diligence, corporate, brand and therapeutic area strategy, strategy implementation, geographic expansion, commercial innovation, R&D redesign and operating model
In the private investment space, Matt leads Bain's Life Science diligence efforts for our private equity clients, and has advised on numerous product, services and IT investment opportunities across the pharmaceutical value chain, plus investment opportunities in life science tools and diagnostics
Prior to joining Bain in 2008, Matt was an associate specialist at the University of California, San Francisco, where he studied the molecular mechanisms that govern cell cycle control and mitosis. He was also a postdoctoral research fellow with Cancer Research UK, focused on the mechanisms that govern cell division with particular emphasis on sister chromatid cohesion.
Matt holds a PhD in genetics from Imperial College London and a BA in chemistry from University of Oxford.